2020-11-29T07:53:16Z https://www.theskygallerypattaya.com/oai/oai.php

oai:theskygallerypattaya.com:10.29328/journal.hjpcr.1001003 2017-06-27 HJPCR:VOL1

MicroRNA Therapeutics in Triple Negative Breast Cancer Sarmistha Mitra<h2>ABSTRACT</h2><p>Breast cancer is a complex disease and one of the main causes of cancer-related mortality in women worldwide. In case of approximately 15% of all breast cancers, three markers i.e. estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptors-2 (HER2) are not expressed, and is commonly termed as triple-negative breast cancer (TNBC). Particularly, TNBC is associated with a higher percentage of breast cancer related mortality, which is often aggressive and most frequently found with a BRCA1 mutation or increased basal marker expression. However, due to the limitations of chemotherapy and radiation based treatment; the current challenge is to establish a new strategy of diagnosis and treatment of TNBC. The deregulation of a number of microRNAs (miRNAs) in breast cancer has been widely reported. Therefore, this review is directed towards enhancing our understanding of the involvement of various miRNAs in the pathology of TNBC, their upregulations and downregulations and the effects on various factors. From recent studies a number of miRNAs are found to be related with TNBC, which have great potential to be used as a biomarker to determine the disease prognosis and predict the fate of disease. Again miRNA can be targeted to be applied as a therapeutic to provide a great benefit to the patients of TNBC by finding a new, safe, and effective treatment strategy.</p> Archives of Pathology and Clinical Research - Heighten Science Publications Corporation 2017-06-27 Review Articlehttps://www.theskygallerypattaya.com/hjpcr/apcr-aid1003.phpenCopyright © Sarmistha Mitra